Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial - 26/03/20

Rachel G. Casseres, BA ^{a, b}, Lisa Prussick, BSc, MD ^{a, b}, Pedro Zancanaro, MD ^a, Brooke Rothstein, MD ^a, Deep Joshipura, MD ^a, Ami Saraiya, MD ^a, Yana Turkowski, MD ^a, Shiu Chung Au, MD ^a, Abdulaziz Alomran, MD ^a, Rana Abdat, MD ^a, Minawaer Abudu, MD ^a, Courtney Kachuk, RN ^a, Nicole Dumont ^a, Alice B. Gottlieb, MD, PhD ^c, David Rosmarin, MD ^{a, ⁎}

^a Tufts Medical Center, Department of Dermatology, Boston, Massachusetts 

^b Tufts University School of Medicine, Boston, Massachusetts 

^c Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, New York 

^∗Correspondence to: David Rosmarin, MD, 800 Washington St, PO Box 114, Boston, MA 02111800 Washington StPO Box 114BostonMA02111